A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects.

Trial Profile

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Siponimod (Primary)
  • Indications Dermatomyositis; Multiple sclerosis; Polymyositis
  • Focus Pharmacokinetics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 13 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jan 2014 According to the ClinicalTrials.gov record, Planned End Date changed from 1 Jan 2014 to 1 Mar 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top